Business Context and Reporting Period
Propanc Biopharma, Inc., a Delaware corporation, filed this Form 8-K on January 13, 2020, to report the entry into material definitive agreements. The company is headquartered in Camberwell, Australia, and operates in the biopharma sector.
Key Financial Metrics and Transaction Details
The filing details two financing transactions involving Convertible Redeemable Promissory Notes funded on January 13, 2020:
- First Investor Transaction:
- Purchase Price: $75,000
- Note Principal: $75,000
- Interest Rate: 8% per annum
- Maturity Date: January 6, 2021
- Second Investor Transaction:
- Purchase Price: $105,000
- Note Principal: $110,250 (includes original issue discount)
- Interest Rate: 8% per annum
- Maturity Date: January 13, 2021
- Total Cash Raised: $180,000
- Total Debt Principal: $185,250
The filing does not provide data on revenue, operating profit, cash flow from operations, or existing debt levels outside of these new obligations.
Material Changes and Terms
The primary material change is the creation of new direct financial obligations. Key terms include:
- Conversion Rights:
- First Note: Convertible after 180 days. Conversion price is based on a 35% discount to the average of the three lowest closing bid prices over the prior 10 trading days, subject to a floor of $3.05 if the market price is under $5.00, or a floor of $3.05 if the market price is $5.00 or higher (whichever is greater/lesser per specific clauses).
- Second Note: Convertible immediately. Fixed conversion price of $2.50 per share for the first 6 months; thereafter, a 35% discount to the lowest closing bid price over the prior 10 trading days.
- Ownership Caps: Conversion is limited to prevent investors from beneficially owning more than 4.99% of the company's common stock, unless increased to 9.99% with 60 days' prior notice.
- Redemption Provisions: The Company may redeem the notes prior to July 5, 2020, at escalating premiums ranging from 110% to 135% of the face amount depending on the timing of redemption.
- Default: Notes become immediately due and payable upon default without demand or notice.
Guidance, Risks, and Unusual Items
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard terms of the debt instruments. The securities were issued as unregistered sales in reliance on Section 4(a)(2) of the Securities Act, based on the transactions being private placements to accredited investors.
Investor Verification Checklist
- Verify the company's current cash position and ability to service the $185,250 principal plus 8% interest by the 2021 maturity dates.
- Assess the potential dilution impact if the notes are converted, particularly given the 35% discount mechanism and the $2.50 fixed price on the Second Note.
- Review the company's capitalization table to determine if the 4.99% beneficial ownership cap will significantly limit the conversion of these notes.
- Confirm the company's liquidity status to evaluate the risk of early redemption at the specified premiums (110%-135%).